BofA notes that Eli Lilly’s (LLY) press release about its GLP-1 pricing deal with the federal government describes price concessions as “less onerous than what was just discussed at the White House press conference.” The firm, which contends that the pricing deal was “probably a good tradeoff overall,” makes no changes to its forecasts at this time and maintains a Buy rating and $950 price target on Eli Lilly shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- GLP-1 price cuts limit Hims advantage, says Needham
- Eli Lilly confirms weight loss drug agreement with U.S. government
- FDA awards second batch of National Priority Vouchers
- TrumpRx GLP-1 pricing ‘less bad than feared’ for Hims & Hers, says Citi
- Eli Lilly’s Stock (LLY) Falls After Trump Announces Deal to Lower Weight-Loss Drug Prices